Journal
CANCER CELL INTERNATIONAL
Volume 22, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s12935-022-02585-z
Keywords
Oncolytic virus (OV); Chimeric antigen receptor (CAR) T-cell therapy; Immunogenic cancer cell death (ICD); Immunotherapy
Categories
Ask authors/readers for more resources
CAR T-cell therapy has shown progress in hematologic malignancies but faces challenges in solid tumors. Combining oncolytic virotherapy with CAR T-cells may be a promising strategy to overcome these obstacles.
Chimeric antigen receptor (CAR) T-cell therapy is a promising and rapidly expanding therapeutic option for a wide range of human malignancies. Despite the ongoing progress of CAR T-cell therapy in hematologic malignancies, the application of this therapeutic strategy in solid tumors has encountered several challenges due to antigen heterogeneity, suboptimal CAR T-cell trafficking, and the immunosuppressive features of the tumor microenvironment (TME). Oncolytic virotherapy is a novel cancer therapy that employs competent or genetically modified oncolytic viruses (OVs) to preferentially proliferate in tumor cells. OVs in combination with CAR T-cells are promising candidates for overcoming the current drawbacks of CAR T-cell application in tumors through triggering immunogenic cell death (ICD) in cancer cells. ICD is a type of cellular death in which danger-associated molecular patterns (DAMPs) and tumor-specific antigens are released, leading to the stimulation of potent anti-cancer immunity. In the present review, we discuss the biological causes of ICD, different types of ICD, and the synergistic combination of OVs and CAR T-cells to reach potent tumor-specific immunity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available